Affimed Therapeutics (AFMD) PT Lowered to $1 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts AFMD Hot Sheet
Price: $0.18 --0%
Rating Summary:
9 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
9 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Stifel analyst Bradley Canino lowered the price target on Affimed Therapeutics (NASDAQ: AFMD) to $1.00 (from $2.00) while maintaining a Hold rating.
You May Also Be Interested In
- Siltronic AG (WAF:GR) (SSLLF) PT Raised to EUR123 at UBS
- Arm Holdings (ARM) PT Lowered to $325 at Barclays
- Citi Upgrades China Longyuan Power Group Corp (916:HK) (CLPXF) to Buy
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
